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MRL/Mp-lpr/lpr (MRL-lpr) mice spontaneously develop autoimmune disease char- 
acterized  by antibodies  to nucleic acids,  immune  complex glomerulonephritis,  and 
death  from renal  failure  (1,  2). They have certain  unique  features  that  make  them 
particularly interesting murine models for systemic lupus erythematosus (SLE).I First, 
they develop massive generalized  lymphadenopathy  associated with proliferation  of 
Lyt-1+23 -  T  cells (3). Second, they exhibit excessive T  helper function  (4, 5). Finally, 
a single autosomal recessive gene, lpr, is responsible for both the ly.mphoproliferation 
and severe autoimmunity of MRL-lpr mice (1). 
Several  immunoregulatory  abnormalities  that  might  contribute  to autoimmunity 
in  MRL-lpr  mice  have  been  identified  (1-11).  These  include  defective  feedback 
suppression in vitro (6), as well as T  helper lymphoproliferation  in vivo (3, 4). Studies 
in two laboratories (10, 11) have focused attention on the syngeneic mixed lymphocyte 
reaction  (SMLR),  which  is decreased  before the onset of clinical  illness.  Failure  to 
develop an  SMLR is an early and consistent  feature in murine  models of SLE and 
may represent a common predisposition  to autoimmunity  (10,  11). 
To clarify the molecular basis for abnormal  immunoregulation  in MRL-lpr mice, 
we  examined  their  ability  to  produce  and  respond  to  interleukin  2  (IL-2).  IL-2, 
previously  called  T  cell  growth  factor,  is  a  lymphokine  produced  by mitogen-  or 
antigen-stimulated  T  cells  (12).  It  is  also produced  during  the  course of a  normal 
SMLR  (13).  IL-2  has  significant  T  cell  regulatory  function  (14-18).  It  stimulates 
thymocyte  proliferation  (14,  15),  provides  helper  activity  for  antibody  production 
(14-16),  facilitates  the  induction  of cytotoxic  T  cells  (14-18),  and  promotes  the 
proliferation of helper and cytotoxic T  lymphocytes in long-term culture (15,  19, 20). 
We found that MRL-lpr mice have a progressive defect in the ability to produce IL- 
2. Furthermore,  spleen cells from MRL-lpr mice fail to respond normally to IL-2. IL- 
2 deficiency precedes the onset of clinical illness and becomes increasingly severe with 
age. 
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We  have  transferred  the  lpr  gene  from  the  MRL-lpr  mice  onto  the  C57BL/6J 
background by eight  cycles of cross-intercross mating. We found that,  like MRL-lpr 
mice, C57BL/6J-lpr/lpr  (B6-1pr) mice develop an autoimmune  disease characterized 
by lymphadenopathy,  antinuclear  antibodies,  and  early  mortality.  Moreover,  they 
lose the ability to produce and respond to IL-2. In contrast, control C57BL/6J-+/+ 
(B6-+/+) mice lacking the lpr gene have normal IL-2 production and response. These 
findings suggest that homozygosity at the lpr locus results in both autoimmunity and 
deficiency  of IL-2  activity.  Our  results  further  suggest  that  IL-2  deficiency  may 
contribute to the immunoregulatory abnormalities  that underlie murine lupus. 
Materials  and Methods 
Mice.  MRL-lpr,  MRL/Mp-+/+  (MRL-+/+),  and  B6-lpr breeding  pairs  were  obtained 
from The Jackson Laboratory, Bar Harbor, Maine, and were maintained at the University of 
California,  San Francisco Vivarium,  and the Veterans  Administration  Medical Center,  San 
Francisco. MRL-lpr and MRL-+/+ are congenic strains with 99.6% genetic homology. MRL- 
+/+  mice lack the autosomal  recessive  gene responsible  for accelerated  autoimmunity and 
lymphoproliferation in MRL-lpr mice (1). 
Culture Medium.  RPMI  1640 medium (Cell Culture Facility, University of California, San 
Francisco, Calif.)  was supplemented with 10% heat-inactivated fetal calf serum (Sterile Systems, 
Inc., Logan, Utah), 1 mM glutamine, 0.1 mM nonessential amino acids, 1 pM sodium pyruvate, 
100  U/ml  penicillin,  100 #g/ml  streptomycin,  50  #g/ml  gentamycin,  and  5  ×  10  -s  M  2- 
mercaptoethanol. This medium was used in the production and testing of IL-2. 
IL-2 Production.  Spleen cells were suspended at a density of 1 ×  10/ml in culture medium 
supplemented with 10/~g/ml concanavalin A (Con A; Miles Laboratories, Inc., Elkhart, Ind.). 
The  cells  were  incubated  in Falcon  3008  multiwell  tissue  culture  plates  (Falcon  Labware, 
Oxnard,  Calif.)  for 36  h  at  37°C  in  a  humidified  atmosphere  containing  5%  CO2.  These 
conditions are optimal for production of IL-2 by murine spleen cells (21). Cells were removed 
from the culture supernatants by centrifugation at  1,500 g for 10 min. Cell-free supernatants 
were subsequently passed through 0.22-/~m filters  (Millipore Corp., Bedford, Mass.)  and stored 
at -20°C. 
IL-2 Assay.  IL-2 activity was  measured  using  a  slight  modification  of the  technique  of 
Smith  et  al.  (22).  Normal  spleen  cells  were  cultured  for 48  h  with  Con A  (2 /~g/ml)  and 
subsequently washed three times in 10 mg/ml a-methyl-v-mannoside (Sigma Chemical Co., St. 
Louis, Mo.). The cells were then incubated in 96-well microtiter plates (Linbro Scientific, Inc., 
Hamden, Conn.) with serial  dilutions of the culture supernatant being tested for IL-2 activity. 
Each well contained 5 ×  103 cells in a volume of 200/tl. Cultures were supplemented with  10 
mg/ml  a-metbyl-D-mannoside to block the  possible  mitogenic effects  of Con  A  in  the  test 
samples.  They were maintained  at  37°C  in  a  humidified  atmosphere of 5%  CO2.  1 /~Ci of 
[3H]thymidine added  during the last  24  h  of a  72-h incubation  yielded optimal  thymidine 
incorporation.  The  cultures  were  then  harvested  onto  glass  fiber  filter  strips,  and  retained 
radioactivity was measured in a Packard liquid scintillation counter (Packard Instrument Co., 
Downers Grove, Ill.). 
In preliminary experiments, it was determined that spleen cells from MRL-+/+, B6-+/+, 
and DBA/2 mice proliferated comparably in response to IL-2. Therefore, we used MRL-+/+ 
spleen cells in our assay of IL-2 activity. 
IL-2 Response.  The assay described above was also used to determine the ability of MRL-lpr 
spleen cells to respond to IL-2. This was accomplished by incubating Con A-activated MRL-lpr 
spleen cells with supernatants  known to contain IL-2. The preparation  of partially  purified 
human IL-2 (Associated Biomedie Systems, Inc., Buffalo, N. Y.) used in these experiments has 
been described previously (23). 
IL-2 Absorption.  Fresh spleen cells from MRL-lpr and MRL-+/+ mice were stimulated with 
Con A  (2 #g/ml)  for 48  h, washed  three  times  in  a-methyl-n-mannoside  (10  mg/ml),  and 
incubated with a standard IL-2 preparation (5 ×  107 cells/ml) for 2 h at 37°C. After incubation, WOFSY,  MURPHY,  ROTHS,  DAUPHINI~E,  KIPPER,  AND  TALAL  1673 
the cells were removed by centrifugation at 1,500 g for 10 min, and the remaining supernatants 
were tested  for IL-2 activity. 
Interleukb2 1 (IL-1) Production.  The IL-1 used in these experiments was generously provided 
by Dr. Robert Mishell of the University of California at Berkeley. Briefly, macrophage culture 
supernatants were derived from PU5-1.8  cells as described  previously (24) and tested for IL-1 
activity in the thymocyte proliferation assay of Farrar et al. (25). Culture supernatants retained 
50% maximum activity in the IL-1 assay at a  1:32 dilution. 
Results 
IL-2 Production by MRL-lpr Spleen Cells.  MRL-lpr mice had a marked defect in IL- 
2 production that was already prominent early in life and increased with age (Fig.  1). 
Culture supernatants derived from 2-mo-old MRL-lpr mice had relatively little IL-2 
activity even at the highest concentration tested  (1:2), and had no activity beyond a 
1:4 dilution.  In contrast, culture supernatants derived from age-matched MRL-+/+ 
mice retained activity through a  1:64 dilution  (Fig.  1 a). By 5 mo of age, the defect in 
IL-2 production was virtually absolute (Fig.  1 b). The reduction in IL-2 activity was 
independent of the duration of culture or the dose of Con A used (Fig. 2). 
Effect  of MRL-lpr  Spleen Cells on  IL-2  Production by  MRL-+ / +  Spleen Cells.  To 
determine whether suppressor cells were responsible for IL-2 deficiency in MRL-lpr 
mice, we co-cultured equal concentrations  (5 ×  106 cells/ml) of lymphocytes from 5- 
mo-old MRL-+/+  and MRL-lpr mice. Control cultures consisted of either MRL-+/ 
+  or MRL-lpr  cells  alone.  In  four separate experiments,  we  found  no evidence  of 
cellular suppression of IL-2 production. A representative experiment is shown in Fig. 
3.  These  results  also  imply  that  MRL-lpr  spleen  cells  do  not  produce  a  soluble 
inhibitor of IL-2 activity. If such an inhibitor were produced, it would have inhibited 
IL-2 activity in the mixed cell cultures as well as in the cultures containing MRL-lpr 
cells only. 
Effect of Macrophage-replacing Factors on IL-2 Production.  IL-2 production  is macro- 
phage dependent (26). Farrar et al. have shown that the requirement for macrophages 
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Fxc.  1.  IL-2 activity in culture supernatants derived from (a) 2-mo-old, and (b) 5-mo-old MRL-lpr 
(C)) and MRL-+/+ (Q) spleen cells. Each point represents the mean value of six individual mice. 
The dotted line shows the stimulatory effect of Con A (10 #g/ml) alone in the IL-2 assay. 1674  INTERLEUKIN 2 DEFICIENCY  IN MICE  BEARING  THE  lpr GENE 
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Fro. 3.  Effect  of MRL-lpr spleen cells on IL-2 production by MRL-+/+ spleen cells. IL-2 activity 
was measured in supernatants  derived from cocultures (&) of MRL-+/+ spleen cells (5 X 106/ml) 
and MRL-lpr spleen cells (5 ×  106/ml). Control  cultures, consisted of either MRL-+/+  (0) or 
MRL-lpr (O) cells alone at a concentration of 5 ×  106/ml. 
can be replaced in vitro by either phorbol myristic acetate (PMA) or the macrophage 
product, IL-1  (26). To determine whether IL-2 deficiency in MRL-lpr mice reflects a 
macrophage defect rather than a primary T  cell defect, we supplemented our cultures 
with  these  macrophage-replacing  factors.  Neither  PMA  nor  IL-1  stimulated  IL-2 
production by Con A-activated MRL-lpr spleen cells, although they did enhance IL- 
2  production  by  control  MRL-+/+  spleen cells  (Fig.  4).  Peak  IL-2  production  by 
MRL-+/+  spleen cells was associated with  10 ng/ml PMA or a  1:10 dilution of our 
IL-1 preparation. MRL-lpr spleen cells failed to produce IL-2 at PMA concentrations 
ranging  from  5  to  20  ng/ml  and  IL-1  dilutions  ranging  from  1:9  to  1:32.  Neither 
PMA nor IL-1 stimulated IL-2 production in the absence of Con A, nor did PMA or 
IL-1 cause significant thymidine incorporation in the IL-2 assay (data not shown). 
Pathologic Features and IL-2 Production in B6-lpr Mice.  The characteristics of B6-1pr 
mice are summarized in Table I. B6-lpr mice had the typical features of disease seen 
in  MRL-lpr  mice:  lymph  nodes  were  increased  in  size  10-20-fold  by  4  mo  of age; 
antinuclear  antibodies were  present  at  6  mo  of age;  and  the  median  survival  was 
shortened  to  284  d,  as compared  with  795  d  in  control  B6-+/+  mice.  B6-lpr  mice 
developed a  defect in IL-2 activity early in life that became progressively more severe 
with age. Although spleen cells from 2-too-old B6-lpr mice produced IL-2 normally in WOFSY,  MURPHY,  ROTHS,  DAUPHINEE,  KIPPER, AND TALAL  1675 
100 
b 
10 
C3 
Q. 
3 
Q. 
8  c 
! 
.-g 
J: 
I- 
1;2  1':8  112  118  1:32  1:1'28 
Sample Dilution 
Fro. 4.  Effect of 1:10 dilution of IL-1 preparation (©) or 10 ng/ml PMA (&) on Con A-induced 
IL-2 production by (a) MRL-lpr and (b) MRL-+/+ spleen cells. These concentrations of IL-1 and 
PMA resulted  in  maximum  IL-2 production  by MRL-+/+ spleen cells. The closed circles (0) 
represent Con A-induced IL-2 production in cultures not supplemented with IL-1 or PMA. 
TABLE  I 
Characteristics of C57BL/ 6J-lpr/lpr mice 
Antinuclear 
Genotype  Axillary lymph node  antibodies at 6  Survival at 
size at 4 mo  mo (number  10 mo:[: 
positive/total) * 
mg/g body wt +SEM  % 
C57BL/6J-lpr/lpr  2.99 ± 0.67  6/6§  37§ 
C57BL/6J-+/+  0.18 + 0.01  0/8  96 
* Sera (1:10 dilution)  tested by indirect  immunofluorescence using rat liver 
sections as substrate (1). 
:[: Percent survival among  27 C57BL/6J-lpr/lpr mice and 24 C57BL/6J-+/+ 
mice. 
§ P <0.005 compared with C57BL/6J-+/+ mice (X  2 analysis of 2 X 2 contin- 
gency table). 
response to Con A, spleen cells from 3-mo-old mice showed a  marked reduction in IL- 
2 activity (Fig. 5). There was virtually no IL-2 activity at 6 mo of age. 
Spleen Cell Response to IL-2.  Con A-stimulated spleen cells from MRL-lpr and B6- 
lpr mice proliferated significantly less in response to standard IL-2 preparations than 
did  spleen  cells  from  age-matched  controls  (Table  II).  Like  the  defect  in  IL-2 
production,  the  defect  in  IL-2  response  was  present  in  2-mo-old MRL-lpr  mice  (P 
<0.05;  t  test for comparison of two independent  means)  and rose dramatically by 5 
mo of age (P <10-5). 
Absorption of lL-2 Activity  by Activated  T Cells.  The failure of MRL-lpr spleen cells to 
respond normally to IL-2 suggested that they might be unable to bind the lymphokine. 
To investigate this possibility, we incubated a standard IL-2 preparation with Con A- 
stimulated lymphocytes from either 5-mo-old MRL-lpr or MRL-+/+  mice. After 2 h 
of incubation  with  activated  MRL-+/+  spleen  cells  (5  ×  10r/ml),  all of the  IL-2 1676  INTERLEUKIN  2  DEFICIENCY  IN  MICE  BEARING THE  lpr GENE 
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TABLe  II 
Spleen Cell Response to IL-2 
Number  Thymidine incorpo- 
Spleen cell source  of mice  IL-2 source  ration 
tested 
cpm 
MRL-lpr  (2-mo-old)  7  Murine*  25,075 ± 6,152¢ 
MRL-+/+ (2-mo-old)  7  Murine  45,454 ±  6,091 
MRL-lpr  (5-mo-old)  6  Murine  3,452 ±  1,660 
MRL-+/+ (5-mo-old)  6  Murine  43,392 ::1:4,417 
MRL-lpr  (5-mo-old)  4§  Human  H  1,010 
MRL-+/+ (5-mo-old)  4  Human  17,773 
B6-lpr (6-mo-old)  4  Human  2,590 ±  1,245 
B6-+/+ (6-mo-old)  4  Human  24,595 ± 6,210 
* Culture supernatant from Con A-stimulated MRL-+/+ cells. 
Mean ±  SE. 
§ Pooled specimen. 
U  Partially purified human IL-2. 
activity had been removed from the supernatant (Fig. 6). In contrast, incubation with 
MRL-lpr cells removed very little, if any, IL-2. 
Discussion 
Culture supernatants  derived from Con A-activated MRL-lpr but not MRL--I-/+ 
spleen cells were deficient in IL-2 activity. In addition, MRL-lpr  spleen cells responded 
poorly to IL-2. These defects were present early in life and became nearly absolute by 
5  mo of age.  These findings suggest  that  deficient IL-2 activity may contribute to 
impaired immunoregulation and to the development of autoimmune disease. WOFSY, MURPHY, 
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FIG. 6.  Activity  of a standard IL-2 preparation before (&) and after absorption with Con A- 
stimulated MRL-Ipr  (O) or MRL-+/+ (0) spleen cells. Absorptions were performed at 37°C for 2 
h using 5 × 107 cells/ml. 
Because MRL-lpr and MRL-+/+  mice are congenic strains, we suspected that the 
lpr gene  might  code for a  product  that  directly or indirectly  caused  deficient  IL-2 
activity  and  impaired  immunoregulation.  This  hypothesis  was  supported  by  our 
finding that C57BL/6J mice bearing the lpr gene also developed early IL-2 deficiency 
and  subsequently  a  lupus-like  illness.  Thus,  in  two  mouse  strains,  the  lpr gene  is 
associated with both IL-2 deficiency and autoimmune disease. 
We  considered  several  mechanisms  through  which  IL-2  deficiency  might  arise. 
Because production of IL-2 is macrophage dependent (26), a macrophage defect could 
result  in  decreased  IL-2  production.  Our  observation  that  neither  IL-1  nor  PMA 
restored  IL-2 production  in MRL-lpr  mice suggests that  IL-2 deficiency is  not  due 
solely  to  a  macrophage  defect.  In  humans,  Con  A  induces  suppressor  cells  that 
suppress IL-2 production  (27). We found no such suppressor cells in MRL-lpr mice, 
nor did MRL-lpr mice produce a soluble inhibitor of IL-2 activity. 
A  structural  abnormality  might  produce  an  IL-2  molecule  lacking  biological 
activity.  However,  this  would  not  easily  explain  the  increasing  severity  of  IL-2 
deficiency with  age.  Alternatively,  spleen  cells  capable of producing  IL-2  may be 
diminished in frequency due to proliferation of other lymphocyte subpopulations. We 
doubt  that  an  alteration  in  cell  ratios  is  solely responsible  for the  IL-2  deficiency 
because this defect is present in young MRL-lpr mice in whom lymphoproliferation 
is mild. Furthermore, the proliferating cells in MRL-lpr mice are Lyt-1+23  -  (3), as are 
the cells that normally produce IL-2 (28). 
Two signals are necessary for normal lymphocytes to proliferate in response to IL- 
2 (22,  29). First, they must be stimulated by mitogen or antigen because receptors for 
IL-2 are expressed on activated T  cells but not on resting T  cells. Second, they must 
be stimulated by IL-2. We have shown that Con A-stimulated MRL-+/+  spleen cells 
can  absorb  IL-2,  whereas  Con  A-stimulated  MRL-lpr  spleen  cells  cannot.  These 
findings imply that the poor response of MRL-lpr spleen cells in the IL-2 assay reflects 
an  actual  or  functional  deficiency  of surface  receptors  for  IL-2.  The  relationship 
between the defect in production of IL-2 and the defect in generation of IL-2 receptors 
is a  problem for further study. However, it does not appear that these defects simply 1678  INTERLEUKIN 2 DEFICIENCY IN MICE BEARING THE lpr GENE 
reflect  a  generalized  failure of Con  A-stimulated responses because certain  Con  A- 
induced  functions, such as cellular suppression of immunoglobulin synthesis  (5), are 
normal even in old MRL-lpr mice. 
The relationship between IL-2 deficiency and autoimmunity is intriguing.  Normal 
immunoregulation depends upon a complex set of cellular interactions (30)  in which 
IL-2 appears to play an important role (14-18).  IL-2 stimulates thymocyte prolifera- 
tion (14,  15), provides helper activity for antibody production (14-16), and facilitates 
the induction  of cytotoxic T  cells  (14-18).  Diminished  IL-2 production  might  alter 
vital  immune  functions  and  thereby  contribute  to  autoimmunity.  Indeed,  the  de- 
pressed SMLR, which is considered to be a  model for abnormal cellular interaction 
in  autoimmune  mice  (10,  11),  may be  due  to  the  deficiency  of IL-2.  There  is  a 
temporal  correlation  between  the  disappearance  of IL-2  activity  and  the  loss  of 
syngeneic reactivity in MRL-lpr mice.  Both  occur early in  life, before the onset  of 
overt clinical disease. The defective cell in the SMLR bears the Lyt-1+23  -  phenotype 
characteristic of IL-2-producing cells (11,  28).  It has recently been shown that IL-2 is 
produced in the course of a  normal SMLR  (13).  Its absence could contribute to the 
abnormal SMLR of MRL-lpr mice. 
The coexistence of T  cell proliferation and reduced IL-2 activity in MRL-lpr mice 
may appear paradoxical. However, it is possible that controlled proliferation of Lyt- 
I+23  -  T  cells requires IL-2-dependent T  cell differentiation.  Uncontrolled prolifera- 
tion  of  Lyt-l÷23  -  T  cells  might  then  arise  as  a  consequence  of IL-2  deficiency. 
Alternatively,  the  stimulus  for lymphoproliferation  in MRL-lpr mice may be IL-2 
independent. 
The  observation  that  IL-2  deficiency  precedes  the  onset  of overt  autoimmune 
disease  in  two strains bearing the lpr gene  (MRL,  C57BL/6J)  raises the possibility 
that  the lpr mutation  is  causally  related  to  murine  lupus  through  defective T  cell 
regulation arising as a consequence of the IL-2 abnormality. 
Summary 
Spleen cells from MRL-lpr and B6-lpr mice have a  marked defect in the ability to 
produce interleukin  2  (IL-2) in response to concanavalin A  stimulation.  This defect 
precedes  the  onset  of clinical  illness,  increases  with  age,  and  eventually  becomes 
virtually absolute. It is not due to cellular suppression of IL-2 production, nor does it 
reflect  the  presence  of a  soluble  inhibitor  of IL-2  activity.  Failure  to  restore  IL-2 
production  with  macrophage-replacing  factors,  such  as  interleukin  1 and  phorbol 
myristic acetate, suggests that  IL-2 deficiency reflects a  primary T  cell defect rather 
than  a  macrophage  defect.  MRL-lpr  and  B6-lpr spleen  cells  also  have  an  age- 
dependent reduction in IL-2 response that apparently results from a deficiency of cell 
surface receptors for IL-2. Congenic MRL-+/+  and B6-+/+ mice, which lack the lpr 
gene responsible for accelerated autoimmunity and lymphoproliferation, have normal 
IL-2 activity. These findings suggest that a  defect in IL-2 activity may contribute to 
impaired  immunoregulation  in  mice  bearing  the  lpr gene.  The  absence  of such  a 
defect  in  MRL-+/+  and  B6-+/+  mice  further  suggests  that  a  single  autosomal 
recessive gene is responsible for the IL-2 deficiency. 
We thank Dr.  Robert Mishell  for his  advice and  assistance  in  these  studies.  We gratefully 
acknowledge  the technical contribution of Chris Kerger and Kathleen Roskos, and thank Sally 
Walsh for help in preparation of the manuscript. WOFSY, MURPHY,  ROTHS,  DAUPHINI~E, KIPPER, AND TALAL  1679 
Received  for publication 5 May 1981 and in revised  form 9June 1981. 
References 
1.  Murphy, E. D., and J. B. Roths.  1978. Autoimmunity and lymphoproliferation: induction 
by mutant gene lpr, and acceleration by a male-associated factor in strain BXSB. In Genetic 
Control of Autoimmune Disease.  N.  R.  Rose,  P.  E.  Bigazzi, and  N.  L. Warner, editors. 
Elsevier  North-Holland, Inc., New York. 207. 
2.  Andrews,  B.  S.,  R.  A.  Eisenberg,  A.  N.  Theofilopoulos,  S.  Izui,  C.  B.  Wilson,  P.  J. 
McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus- 
like syndromes. Clinical and immunopathological manifestations in several strains..]. Exp. 
Med.  148:1198. 
3.  Theofilopoulos, A. N., R. A. Eisenberg, M. Bourdon, J.  S. Crowell, Jr., and F. J.  Dixon. 
1979. Distribution  of lymphocytes identified  by surface markers  in  murine  strains  with 
systemic lupus erythematosus-like syndromes.J. Exp. Med.  149:516. 
4.  Sawada, S., and N. Talal.  1979. Evidence for a helper cell promoting anti-DNA antibody 
production in murine lupus. Arthritis Rheum. 22:655.  (Abstr.) 
5.  Theofilopoulos, A.  N.,  D.  L.  Shawler,  R.  A.  Eisenberg,  and  F. J.  Dixon.  1980. Splenic 
immunoglobulin-secreting cells and their regulation in autoimmune mice.J. Exp. Med. 151: 
446. 
6.  Gershon, R. K., M. Horowitz, J. D. Kemp, D. B. Murphy, and E. D. Murphy.  1978. The 
cellular site of immunoregulatory breakdown in the lpr mutant mouse. In Genetic Control 
of Autoimmune Disease.  N.  R.  Rose, P.  E.  Bigazzi, and  N.  L. Warner, editors.  Elsevier 
North-Holland, Inc., New York. 223. 
7.  Creighton, W. D., D. H. Katz, and F.J. Dixon. 1979. Antigen-specific immunocompetency, 
B cell  function, and  regulatory helper  and  suppressor T  cell  activities  in spontaneously 
autoimmune mice. J. Immunol. 123:2627. 
8.  Izui, S., and R. A. Eisenberg.  1980. Circulating anti-DNA-rheumatoid factor complexes in 
MRL/1 mice. Clin. Immunol. Immunopathol. 155:536. 
9.  Steinberg, A. D., J.  B. Roths, E. D. Murphy, R. T. Steinberg, and E. S. Raveche.  1980. 
Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/ 
Mp-lpr  / lpr mice.J. Immunol. 125:871. 
10.  Hom, J. T., and N. Talal. Disordered immunologic regulation. In Immuno-Dynamics. Vol. 
III. R. S. Krakauer, editor. Elsevier North-Holland, Inc., New York. In press. 
11.  Glimcher, L. H., A. D. Steinberg, S. B. House, and I. Green.  1980. The autologous mixed 
lymphocyte reaction in strains of mice with autoimmune disease. J. Immunol. 125:1832. 
12.  Gillis,  S., M. M. Ferm, W. Ou, and K. S. Smith. 1978. T cell growth factor: parameters of 
product!on and a quantitative microassay for activity. J. Immunol. 120:2027. 
13.  Lattime, E. C., S. Gillis, C. David, and O. Stutman.  1981. Interleukin-2, production in the 
syngeneic mixed lymphocyte reaction. Eur. J. Immunol. 11:69. 
14.  Farrar,  J.  j.,  P.  L.  Simon,  W.  J.  Koopman,  and  J.  Fuller-Bonar.  1978. Biochemical 
relationship  of thymocyte  mitogenic  factor  and  factors  enhancing  humoral  and  cell- 
mediated immune responses.J. Immunol. 121:1353. 
15.  Watson, J., s. Gillis, j. Marbrook, D. Mochizuki, and K. A. Smith. 1979. Biochemical and 
biological characterization of lymphocyte regulatory molecules. I. Purification of a class of 
murine lymphokines.J. Exp.  Med.  150:849. 
16.  Watson, J.,  L. A.  Aarden, J.  Shaw, and V.  Paetkau.  1979. Molecular and  quantitative 
analysis of helper T  cell-replacing factors on the induction of antigen-sensitive B and T 
lymphocytes.J. Immunol. 122:1633. 
17.  Shaw, J.,  V.  Monticone,  G.  Mills,  and  V.  Paetkau.  1978. Effects of co-stimulator on 
immune responses  in vitro. J. Irnmunol. 120:1974. 
18.  Kruisbeek, A. M., J. J. Zijlstra, and T. J. M. Kr6se.  1980. Distinct effects of T cell growth 1680  INTERLEUKIN 2 DEFICIENCY  IN MICE BEARING THE lpr GENE 
factors and  thymic epithelial  factors on the  generation  of cytotoxic T  lymphocytes by 
thymocyte subpopulations.J.  Immunol. 125"995. 
19.  Gillis, S., P. E. Baker, F. W. Ruscetti, and K. A. Smith.  1978. Long-term culture of human 
antigen-specific cytotoxic T-cell lines.J.  Exp.  Med. 148:1093. 
20.  Watson, J.  1979. Continuous proliferation ofmurine antigen-specific helper T lymphocytes 
in culture.J.  Exp.  Med.  150:1510. 
21.  Rosenberg, S. A., P. J.  Spiess,  and S. Schwarz.  1978. In vitro growth of murine T  cells. I. 
Production of factors necessary for T cell growth. J. Immunol. 121:1946, 
22.  Smith, K. A., S. Gillis, P. E. Baker, D. MacKenzie, and F. W. Ruscetti.  1979. T-cell growth 
factor-mediated T-cell proliferation. Ann. N.  E  Acad. Sci. 332:423. 
23.  Mier, J. W., and R. C. Gallo.  1980. Purification and some characteristics of human T-cell 
growth factor from phytohemagglutinin-stimulated  lymphocyte-conditioned media. Proc. 
Natl.  Acad. ScL  U. S. A. 77:6134. 
24.  Mishell,  R. I.,J. M. Shiigi, B. Mishell,  K. H. Grabstein, and S. M. Shiigi.  Prevention of the 
immunosuppressive effects  of glucocorticosteroids by cell-free  factors from adjuvant-acti- 
vated accessory cells. Immunopharmacol. 2:233. 
25.  Farrar, W. L., S. B. Mizel, and J. J. Farrar.  1980. Participation of lymphocyte activating 
factor (interleukin- 1) in the induction of cytotoxic T  cell responses. J. Immunol. 124:137 I. 
26.  Farrar,  J.  J.,  S.  B.  Mizel,  J.  Fuller-Farrar,  W.  L.  Farrar,  and  M.  L.  Hilfiker.  1980. 
Macrophage-independent  activation  of helper  T  cells.  I.  Production of interleukin  2. J. 
Immunol. 125:793. 
27.  Northoff, H., C. Carter, and J. J. Oppenheim.  1980. Inhibition of concanavalin A-induced 
human lymphocyte mitogenic factor (interleukin  2) production by suppressor T  lympho- 
cytes. J. Immunol. 125:1823. 
28.  Shaw, J., B. Caplan, V. Paetkau, L. M. Pilarski,  T. L. Delovitch, and I. C. F. Mackenzie. 
1980. Cellular origins of co-stimulator (IL-2) and  its  activity in cytotoxic T  lymphocyte 
responses.J.  Immunol. 124:2231. 
29.  Coutinho, A., E.  Larsson, K. Gr6nvik, and J. Anderson.  1979. Studies on T  lymphocyte 
activation. II. The target cells for concanavalin A-induced growth factors. Eur. J. Immunol. 
9:592. 
30.  Cantor, H., and R. K. Gershon.  1979. Immunological circuits: cellular composition. Fed. 
Proc. 38:2058. 